Aspirin-triggered proresolving mediators stimulate resolution in cancer.
Publication Title
Proceedings of the National Academy of Sciences of the United States of America
Document Type
Article
Publication Date
3-26-2019
Keywords
eicosanoids; inflammation; metabolomics; metastasis; resolvins
Abstract
Inflammation in the tumor microenvironment is a strong promoter of tumor growth. Substantial epidemiologic evidence suggests that aspirin, which suppresses inflammation, reduces the risk of cancer. The mechanism by which aspirin inhibits cancer has remained unclear, and toxicity has limited its clinical use. Aspirin not only blocks the biosynthesis of prostaglandins, but also stimulates the endogenous production of anti-inflammatory and proresolving mediators termed aspirin-triggered specialized proresolving mediators (AT-SPMs), such as aspirin-triggered resolvins (AT-RvDs) and lipoxins (AT-LXs). Using genetic and pharmacologic manipulation of a proresolving receptor, we demonstrate that AT-RvDs mediate the antitumor activity of aspirin. Moreover, treatment of mice with AT-RvDs (e.g., AT-RvD1 and AT-RvD3) or AT-LXA
Clinical Institute
Cancer
Specialty/Research Institute
Institute for Systems Biology
